ストックスクリーナーアプリを入手
38.78
10.56%
-4.58
アフターアワーズ：
40.71
1.93
+4.98%
前日終値:
$43.36
開ける：
$40.25
24時間の取引高:
18,578
Relative Volume:
0.52
時価総額：
$256.59M
収益：
-
当期純損益:
$-7.12M
株価収益率:
-16.86
EPS:
-2.3
ネットキャッシュフロー:
$-6.82M
1週間 パフォーマンス:
-7.58%
1か月 パフォーマンス:
+29.27%
6か月 パフォーマンス:
+145.75%
1年 パフォーマンス:
+4,796%
1日の値動き範囲:
$38.78
$43.59
1週間の範囲:
$38.78
$46.60
52週間の値動き範囲:
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
名前
Monopar Therapeutics Inc
セクター
電話
(847) 388-0349
住所
1000 SKOKIE BLVD SUITE 350, WILMETTE
MNPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
38.78 | 256.59M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-19 | 再開されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Piper Sandler | Overweight |
| 2024-10-11 | 開始されました | Rodman & Renshaw | Buy |
| 2021-01-28 | 開始されました | ROTH Capital | Buy |
Monopar Therapeutics Inc (MNPR) 最新ニュース
Geode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) - Defense World
Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 - Yahoo
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 - The Manila Times
Why These 15 Healthcare Stocks Are Surging in 2025 - Insider Monkey
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
(MNPR) Investment Analysis - news.stocktradersdaily.com
Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com
(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com
Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks
Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada
HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World
Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World
Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo
Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World
Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq
Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN
Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks
Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks
Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks
Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks
Monopar Therapeutics Inc. (MNPR) reports earnings - Quartz
Monopar Therapeutics SEC 10-K Report - TradingView
Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance
Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday - Defense World
Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha
Piper Sandler sets Monopar stock at $76 with Overweight rating - Investing.com
Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential - TipRanks
Piper Sandler sets Monopar stock at $76 with Overweight rating By Investing.com - Investing.com UK
(MNPR) Trading Report - news.stocktradersdaily.com
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 19% loss last week hit both individual investors who own 33% as well as institutions - Simply Wall St
Monopar Therapeutics: Strong Data, But There Are Risks (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics appoints new CFO - Investing.com
Monopar Therapeutics Appoints Quan Vu as New CFO - TipRanks
Monopar Therapeutics Inc Says On Feb 28, CFO Karthik Radhakrishnan'S Employment Terminated - Marketscreener.com
Monopar Therapeutics appoints new CFO By Investing.com - Investing.com Australia
Monopar Therapeutics appoints new board member - Investing.com
Monopar Therapeutics appoints new board member By Investing.com - Investing.com UK
Monopar Therapeutics Appoints Lavina Talukdar to Board - TipRanks
Trend Tracker for (MNPR) - Stock Traders Daily
Copper wired: Monopar to electrify Wilson disease? - BioWorld Online
Q1 EPS Estimate for Monopar Therapeutics Raised by Analyst - MarketBeat
Learn to Evaluate (MNPR) using the Charts - Stock Traders Daily
Brookline Capital Management Forecasts MNPR Q1 Earnings - Defense World
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - RTTNews
Monopar Therapeutics Inc (MNPR) 財務データ
収益
当期純利益
現金流量
EPS
5.24%
大文字化:
|
ボリューム (24 時間):